Bayer Targets Vision Loss With $2.45 Billion Biotech Acquisition
Leverkusen, Wednesday, 6 May 2026.
Bayer’s $2.45 billion acquisition of Perfuse Therapeutics secures a breakthrough clinical implant that demonstrated the remarkable potential to reverse vision loss, strategically bolstering the pharmaceutical giant’s aging product lineup.
Structuring the Multi-Billion Dollar Buyout
On Wednesday, May 6, 2026, German pharmaceutical and agricultural conglomerate Bayer (ETR: BAYN) confirmed its agreement to acquire Perfuse Therapeutics [1][2]. The transaction is heavily back-loaded, featuring an upfront cash payment of $300 million, which represents approximately 12.245 percent of the total potential deal value [1][2][3][4][6]. The remaining $2.15 billion, or up to $2.15 billion, is entirely contingent upon Perfuse achieving specific developmental, regulatory, and commercial milestones [2][3][4][7]. The biopharmaceutical industry frequently utilizes milestone-based acquisition structures to mitigate financial risk during the highly unpredictable clinical trial phases [GPT]. This acquisition represents Bayer’s most significant biopharmaceutical purchase since it bought Vividion Therapeutics for up to $2 billion in 2021 [6] and its $4 billion takeover of AskBio in 2020 [1]. The deal remains subject to standard antitrust clearances and the approval of Perfuse stockholders [2][3][7], though an exact closing date has not been finalized [3].
Strategic Advisory and Corporate Context
Perfuse Therapeutics, which operates out of South San Francisco, California, and Durham, North Carolina [3], brings a highly specialized pipeline to Bayer’s portfolio. To navigate the transaction, Bayer retained BofA Securities and Baker McKenzie as its advisors, while Perfuse enlisted Centerview Partners LLC and Goodwin Procter LLP [3]. For Bayer, a company that reported total sales of 45.6 billion euros and research and development expenses of 5.8 billion euros in fiscal year 2025 alongside a workforce of approximately 88,000 employees [3], a $300 million upfront commitment represents a calculated, relatively low-risk entry into a potentially lucrative therapeutic market.
The Clinical Promise of PER-001
The centerpiece of the acquisition is full control over PER-001, an investigational Phase II drug designed to treat ocular diseases such as glaucoma and diabetic retinopathy [2][3][4][7]. PER-001 is a small molecule endothelin receptor antagonist (ERA) [2][3][7]. It functions by blocking endothelin-1, a potent vasoconstrictor that is typically upregulated in patients suffering from glaucoma, diabetic retinopathy, and age-related macular degeneration [4]. The drug is delivered directly into the eye via a bio-erodible intravitreal implant designed to be administered every six months [6]. By inhibiting endothelin signaling, PER-001 aims to enhance blood flow to the retina, reduce inflammation, and ultimately prevent retinal cell death [4][6].
Evaluating Phase 2 Trial Efficacy
Clinical data reported in 2025 from Phase 2a trials provided the compelling evidence Bayer needed to execute the buyout [4][6]. During these trials, PER-001 demonstrated the ability to actually reverse progressive vision loss in glaucoma patients while improving optic nerve blood flow [6]. In diabetic retinopathy patients, the implant improved overall vision and reduced retinal ischemia [6]. Despite these promising results and Perfuse’s previously stated intentions to initiate larger pivotal trials in the latter half of 2025, there are currently no Phase 3 studies registered on federal trial databases listing PER-001 or Perfuse as the sponsor [4]. Bayer’s official communications classify the drug as still being in Phase II clinical development without providing a definitive timeline for future trials [2][3][4].
Market Dynamics and the Eylea Factor
The market for effective ophthalmology treatments is vast and expanding. Glaucoma currently affects approximately 76 to 80 million people globally, a number projected to surge to 112 million by 2040 [3]. Similarly, diabetic retinopathy impacts around 146 million individuals worldwide, with forecasts suggesting an increase to 160 million by 2045 [3]. Of those, an estimated 25 million people suffer from vision-threatening forms of the disease, and 1.3 million are blind [3]. Combined, these ocular conditions impact more than 230 million people globally, representing a high unmet medical need [5]. Sevgi Gurkan, M.D., the founder and CEO of Perfuse Therapeutics, noted that Bayer’s global scale and resources are essential to unlocking PER-001’s full potential to change the trajectory of human blindness [3][6].
Securing a Successor for an Aging Pipeline
From a strategic standpoint, acquiring Perfuse is a necessary defensive and offensive maneuver for Bayer. Last year, the company’s top-selling pharmaceutical product was the eye drug Eylea (aflibercept), an anti-VEGF treatment partnered with Regeneron [1][4]. Eylea generated 3.11 billion euros (approximately $3.7 billion) in sales for Bayer in Europe last year [4][6]. However, the drug has recently gone off-patent and is facing mounting pricing pressures and increased market competition [1][6]. While Bayer’s cell therapy unit, BlueRock Therapeutics, initiated a Phase 1/2a study for primary photoreceptor diseases last year, the company’s late-stage pipeline has predominantly skewed toward oncology, cardiovascular, and renal diseases [4]. Securing PER-001 provides Bayer with a much-needed, advanced clinical asset to eventually succeed Eylea [4][6].